Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NCAPD2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NCAPD2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NCAPD2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NCAPD2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NCAPD2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NCAPD2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0140014 | Colorectum | AD | mitotic nuclear division | 78/3918 | 287/18723 | 6.48e-03 | 4.05e-02 | 78 |
GO:01400141 | Colorectum | MSS | mitotic nuclear division | 70/3467 | 287/18723 | 7.48e-03 | 4.72e-02 | 70 |
GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
GO:000007011 | Esophagus | ESCC | mitotic sister chromatid segregation | 138/8552 | 168/18723 | 1.37e-22 | 2.63e-20 | 138 |
GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
GO:00070761 | Esophagus | ESCC | mitotic chromosome condensation | 15/8552 | 17/18723 | 3.48e-04 | 2.03e-03 | 15 |
GO:014001411 | Liver | HCC | mitotic nuclear division | 174/7958 | 287/18723 | 3.74e-10 | 1.23e-08 | 174 |
GO:0000070 | Liver | HCC | mitotic sister chromatid segregation | 110/7958 | 168/18723 | 1.42e-09 | 4.25e-08 | 110 |
GO:00008191 | Liver | HCC | sister chromatid segregation | 128/7958 | 202/18723 | 1.59e-09 | 4.73e-08 | 128 |
GO:0007059 | Liver | HCC | chromosome segregation | 197/7958 | 346/18723 | 3.57e-08 | 7.87e-07 | 197 |
GO:0098813 | Liver | HCC | nuclear chromosome segregation | 157/7958 | 281/18723 | 3.82e-06 | 4.95e-05 | 157 |
GO:0048285 | Liver | HCC | organelle fission | 254/7958 | 488/18723 | 1.07e-05 | 1.23e-04 | 254 |
GO:0000280 | Liver | HCC | nuclear division | 220/7958 | 439/18723 | 6.90e-04 | 4.25e-03 | 220 |
GO:01400145 | Oral cavity | OSCC | mitotic nuclear division | 191/7305 | 287/18723 | 1.99e-21 | 3.70e-19 | 191 |
GO:00000702 | Oral cavity | OSCC | mitotic sister chromatid segregation | 118/7305 | 168/18723 | 1.89e-16 | 1.48e-14 | 118 |
GO:00008193 | Oral cavity | OSCC | sister chromatid segregation | 135/7305 | 202/18723 | 8.88e-16 | 6.52e-14 | 135 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NCAPD2 | SNV | Missense_Mutation | novel | c.2878N>C | p.Glu960Gln | p.E960Q | Q15021 | protein_coding | tolerated(0.18) | benign(0.077) | TCGA-22-5479-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | SD |
NCAPD2 | SNV | Missense_Mutation | novel | c.3940N>G | p.Pro1314Ala | p.P1314A | Q15021 | protein_coding | tolerated(0.06) | benign(0.005) | TCGA-33-AASI-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | PD |
NCAPD2 | SNV | Missense_Mutation | rs199672478 | c.3461N>G | p.Asn1154Ser | p.N1154S | Q15021 | protein_coding | tolerated(0.61) | benign(0.015) | TCGA-43-A475-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
NCAPD2 | SNV | Missense_Mutation | novel | c.2407N>A | p.Glu803Lys | p.E803K | Q15021 | protein_coding | deleterious(0.02) | benign(0.02) | TCGA-56-A5DR-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
NCAPD2 | SNV | Missense_Mutation | novel | c.1501N>A | p.Glu501Lys | p.E501K | Q15021 | protein_coding | deleterious(0.03) | benign(0.146) | TCGA-63-A5ML-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | vinorelbine | SD |
NCAPD2 | SNV | Missense_Mutation | novel | c.1663N>C | p.Glu555Gln | p.E555Q | Q15021 | protein_coding | tolerated(0.12) | benign(0.042) | TCGA-94-7943-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
NCAPD2 | SNV | Missense_Mutation | rs780825688 | c.334N>A | p.Ala112Thr | p.A112T | Q15021 | protein_coding | tolerated(0.41) | benign(0.188) | TCGA-94-8490-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
NCAPD2 | SNV | Missense_Mutation | rs773097640 | c.4181N>T | p.Ala1394Val | p.A1394V | Q15021 | protein_coding | tolerated(0.06) | benign(0.138) | TCGA-L3-A4E7-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
NCAPD2 | SNV | Missense_Mutation | novel | c.3022A>C | p.Lys1008Gln | p.K1008Q | Q15021 | protein_coding | tolerated(0.17) | benign(0.001) | TCGA-MF-A522-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
NCAPD2 | SNV | Missense_Mutation | novel | c.1673N>T | p.Glu558Val | p.E558V | Q15021 | protein_coding | deleterious(0.01) | probably_damaging(0.949) | TCGA-NC-A5HI-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |